Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients
Status:
Terminated
Trial end date:
2019-08-14
Target enrollment:
Participant gender:
Summary
Afuresertib, an AKT inhibitor, has shown in vitro and in vivo activity in multiple myeloma
models. AKT inhibitor has also demonstrated encouraging clinical activity in multiple
myeloma. This study is designed to determine the tolerability, safety, pharmacokinetics and
efficacy of afuresertib as monotherapy in Japanese relapsed multiple myeloma patients. This
is an open label, dose-escalating, phase I study. Afuresertib will be given daily until the
subjects meet any study treatment withdrawal criteria including disease progression. A total
of up to 24 subjects will be enrolled in the study.